Calidi Biotherapeutics, Inc.
CLDI
$1.59
$0.053.25%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.03M | -19.91M | -19.95M | -19.85M | -19.90M |
| Total Depreciation and Amortization | 1.68M | 1.65M | 1.62M | 1.58M | 1.56M |
| Total Amortization of Deferred Charges | -- | -- | 4.00K | 13.00K | 29.00K |
| Total Other Non-Cash Items | 1.39M | 1.71M | 2.12M | 1.82M | 1.98M |
| Change in Net Operating Assets | -2.33M | -4.74M | -5.47M | -5.94M | -6.65M |
| Cash from Operations | -18.28M | -21.29M | -21.67M | -22.38M | -22.99M |
| Capital Expenditure | -118.00K | -120.00K | -96.00K | -75.00K | -18.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -50.00K | -50.00K | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -168.00K | -170.00K | -96.00K | -75.00K | -18.00K |
| Total Debt Issued | -- | -- | 0.00 | 600.00K | 600.00K |
| Total Debt Repaid | -867.00K | -2.49M | -2.48M | -2.10M | -3.53M |
| Issuance of Common Stock | 11.96M | 16.66M | 29.80M | 27.44M | 32.95M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.42M | 3.29M | 2.91M | 846.00K | 2.44M |
| Cash from Financing | 14.51M | 17.46M | 30.23M | 26.79M | 32.46M |
| Foreign Exchange rate Adjustments | 7.00K | 14.00K | 22.00K | -11.00K | -30.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.93M | -3.99M | 8.48M | 4.33M | 9.42M |